Approaching the sequencing of bispecific antibodies and CAR-T in multiple myeloma

Mohamad Mohty, MD, PhD, Saint-Antoine Hospital, Paris, France, provides insight into approaching the sequencing of bispecific antibodies and CAR T-cell therapy in patients with multiple myeloma (MM) at early relapse. Prof. Mohty notes the high efficacy of approved CAR T-cell constructs and emphasizes that the use of CAR-T is preferred wherever possible. However, he also highlights the benefit of bispecifics for patients requiring an immediate off-the-shelf treatment option to slow rapid disease progression. This interview took place at the 52nd Annual Meeting of the EBMT in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Видео Approaching the sequencing of bispecific antibodies and CAR-T in multiple myeloma канала VJHemOnc – Video Journal of Hematology & HemOnc